Ann: Positive PDCO opinion and A$20m Placement, page-75

First 75 Last

Share
Profile

Follow
raisinsareheresy

253 Posts.

103

01/11/21

17:25

Post #: 57237436
Share

Originally posted by waynesworld: ↑

what are the chances Sarepta is in?.. @arjay

We got about everything on our wish list albeit the licencing agreement still seems elusive. Elusive or in the shadows! What are the chances Sarepta is in could equally be rephrased what are the chances Roche is in? Lets look at the significant market opportunity that ANP highlighted on slide 16.

The point is made in the presentation that ATL1102 has potential for multiple clinical applications. The point is also made, again in the presentation, that Roche acquired exclusive non-US rights for SRP-9001 for US$1.15B upfront plus US$1.7B milestone plus royalties. We generally look at the Roche-Sarepta licensing agreement from the point of view of Sarepta whereas it actually makes more sense upside down. Roche would be the perfect partner not only in DMD but in new potential disease settings including diabetic, respiratory and age-related diseases for which ANP were recently granted new provisional patents. That's on top of MS and other disease indications for which ANP hold existing patents.

Its true that Roche would be a little gun-shy about its dalliance with gene therapy and RNA therapeutics. Firstly, results for SRP-9001 have been underwhelming and secondly, its phase 3 clinical trial of tominersen in Huntington's Disease was halted early. Just to recap tominersen is an ASO that was in-licensed from Ionis.

Undoubtedly, Roche and Ionis are both hoping for a win. Somehow the old expression of killing two birds with one stone seems apt.

Expand

I did notice the detail that the slide went into regarding the Roche-Sarepta deal. I’m not sure how relevant that was to include given the revenue projections were already there. It’s always nice to highlight the value big pharma see in a market, but I’m curious as to what’s prompted the detailed partnership references here..

ANP Price at posting: 24.0¢ Sentiment: Hold Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

MIN

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

There are more pages in this discussion • 92 more messages in this thread...

First 75 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 7.9¢		Change -0.002(2.47%)		Mkt cap ! $81.90M

Open	High	Low	Value	Volume
8.0¢	8.0¢	7.9¢	$230.1K	2.904M

Buyers (Bids)

No.	Vol.	Price($)
1	51000	7.9¢

Sellers (Offers)

Price($)	Vol.	No.
8.0¢	163520	2

View Market Depth

No.	Vol.	Price($)
1	51000	0.079
18	1244001	0.078
10	1037506	0.077
9	894271	0.076
10	1100649	0.075

Price($)	Vol.	No.
0.080	163520	2
0.081	344626	2
0.082	150000	1
0.083	368750	3
0.084	200000	1

Last trade - 15.57pm 01/11/2024 (20 minute delay)

PER (ASX) Chart

Ann: Positive PDCO opinion and A$20m Placement, page-75

Top Stories

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Buyers (Bids)

Sellers (Offers)